News & Publications



Eximo Medical Receives FDA Clearance for B-Laser™ Atherectomy System to Treat Peripheral Artery Disease (Including ISR)

Eximo Medical Ltd. announced today it has received 510(k) clearance from the U. S. Food & Drug Administration (FDA) for its B-Laser™ Atherectomy System for Peripheral Artery Disease (PAD). B-Laser™ is a transformative 355nm wavelength laser technology designed to address unmet clinical needs for treating multiple vascular indications.

Read More

Cardiovascular Systems announces launch of Peripheral Orbital Arterectomy System outside the USA

Cardiovascular Systems Inc. (CSI), a medical device company developing and commercialising interventional treatment systems for patients with peripheral and coronary artery disease, has announced that the first patient in Hong Kong has been treated with its Stealth 360 Peripheral Orbital Atherectomy System (OAS). The Hong Kong case is the first commercial use of Peripheral OAS outside of the USA.

Read More

Virtual reality for wound care patients a Canadian first

Virtual reality is being used to help patients undergoing wound care at Rockyview General Hospital to help ease pain and anxiety during treatment — a first of its kind in Canada. Two Samsung Gear virtual reality headsets were anonymously donated to the hospital after the donor saw research on the benefits of virtual reality during treatment.

Read More

AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of the Thermal Burns at Premier U.S. Military Conference

Avita Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting Device were presented in the plenary session at the U.S. Defense Department Military Health System Research Symposium (MHSRS) in Kissimmee, Florida. The results were presented by James H. Holmes, IV, MD, FACS Wake Forest Baptist Medical Center, Winston-Salem North Carolina.

Read More